Lexicon Pharmaceuticals (LXRX, Financial) experienced a significant stock drop of 5.04%, with the price at $0.677 per share. The trading volume reached 2.346 million shares, with a turnover rate of 0.65% and a volatility of 5.91%. Recent financial reports show revenue of $1.75 million, a net loss of $64.81 million, and earnings per share of -$0.18. The gross profit was $1.55 million, and the P/E ratio stood at -0.92.
Among six rating institutions, 67% recommend buying, while 33% suggest holding. The biotechnology sector, where Lexicon operates, saw a slight increase of 0.19%. The company focuses on developing treatments for neuropathic pain and heart failure.
